Phathom Pharmaceuticals upgraded by Goldman Sachs with a new price target
$PHAT
Biotechnology: Pharmaceutical Preparations
Health Care
Goldman Sachs upgraded Phathom Pharmaceuticals from Sell to Neutral and set a new price target of $48.00 from $40.00 previously